RT Journal Article
SR Electronic
T1 Larazotide Acetate for Treatment of Celiac Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.06.20189324
DO 10.1101/2020.09.06.20189324
A1 Abu-Zaid, Ahmed
A1 Alhaddab, Noor Tariq
A1 Alnujaidi, Razan Abdulkarim
A1 Alharbi, Hadeel Abdulaziz
A1 Alangari, Fulwah
A1 Alyahyawi, Naseem
A1 Kamal, Aminah
A1 Altowairqi, Abdulaziz Khalaf
A1 Alhabeeb, Habeeb
A1 Almustanyir, Sami
A1 Alyoubi, Reem Abdullah
YR 2020
UL http://medrxiv.org/content/early/2020/09/08/2020.09.06.20189324.abstract
AB Purpose The standard of care for treatment of celiac disease (CD) is a stringent lifetime glutenfree diet (GFD), which is very challenging. Larazotide acetate (AT-1001) is an anti-zonulin which functions as a gut permeability regulator for treatment of CD. We endeavored to conduct a systematic review and meta-analysis of all randomized controlled trials (RCTs) which studied the efficacy and safety of larazotide acetate in patients with CD.Methods We examined four databases from inception to 20-August-2020 using related keywords. We identified all relevant RCTs and judged their risk of bias. We pooled continuous outcomes as mean difference and dichotomous outcomes as risk ratio with 95% confidence interval under fixed-effects meta-analysis model.Results Four RCTs met our eligibility criteria, comprising 626 patients (larazotide acetate, n = 465, placebo, n = 161). Three and two studies reported outcomes of patients undergoing gluten challenge and GFD, respectively. For change in lactulose-to-mannitol ratio, the overall effect estimate did not reveal a significant difference between larazotide acetate and placebo groups. For change in total gastrointestinal symptom rating scale (GSRS), subgroup analysis showed that larazotide acetate significantly yielded better symptomatic improvement in the gluten challenge but not gluten free subgroup. Similar finding was found for change in celiac-disease GSRS (CD-GSRS) favoring the gluten challenge over gluten free subgroup. When compared to placebo, larazotide acetate favorably reduced the adverse event (AE) of gluten-related diarrhea in patients who underwent gluten challenge. Other AEs were comparable between both treatment groups.Conclusions Larazotide acetate is well-endured and superior to placebo in alleviating gastrointestinal symptoms.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable or required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are included within the article.